Abstract:

Objective To measure mRNA levels of the CTAs OIP5 and CTCFL in glioma patients and investigate the suitability of the encoded proteins as targets in glioma immunotherapy. Methods RT-PCR was used to measure levels of OIP5 and CTCFL mRNAs in 92 tissue specimens and explore the correlation of OIP5 and CTCFL expression with clinical indices. Results Expression rates of OIP5 and CTCFL were 18.47％（17/92）and 20.65%（19/92），respectively. DNA sequencing results confirmed that RT-PCR synthesis was successful. Statistical analysis showed that OIP5 and CTCFL expression had no correlation with any clinical indices including sex，age，pathological grading，histological subtypes and Karnofsky performance score（P>0.05）. Conclusion OIP5 and CTCFL are expressed specifically in glioma，but expression rates are low. Thus the feasibility of targeting these proteins as antigens in immunotherapy requires further study.

Key words: Glioma, Cancer-testis antigen, OIP5, CTCFL, Tumor immunotherapy